JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus

J Invest Dermatol. 2016 Jun;136(6):1281-1283. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23.

Authors

Joerg Wenzel¹, Nadine van Holt², Judith Maier², Maria Vonnahme³, Thomas Bieber², Dominik Wolf³

Affiliations

¹ Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany. Electronic address: joerg.wenzel@ukb.uni-bonn.de.
² Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany.
³ Medical Clinic 3, Hematology, Oncology and Rheumatology, University Hospital of Bonn, Bonn, Germany.

PMID: 26916391
DOI: 10.1016/j.jid.2016.02.015

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Female
Humans
Janus Kinase 1 / antagonists & inhibitors*
Janus Kinase 2 / antagonists & inhibitors*
Lupus Erythematosus, Cutaneous / drug therapy*
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
STAT Transcription Factors / antagonists & inhibitors
STAT Transcription Factors / physiology

Substances

Nitriles
Pyrazoles
Pyrimidines
STAT Transcription Factors
ruxolitinib
Janus Kinase 1
Janus Kinase 2